The fact
The deal aligns with Servier's strategic refocus on oncology, a key therapeutic area.
The transaction strengthens the French group's cancer treatment portfolio.
2 sources — click a link to read an article on the topic:
The deal aligns with Servier's strategic refocus on oncology, a key therapeutic area.
The transaction strengthens the French group's cancer treatment portfolio.